A multicenter, randomized, double-blind, placebo-controlled, parallel-group, confirmatory study of AS-3201 in patients with diabetic peripheral neuropathy (Phase III).
Phase of Trial: Phase III
Latest Information Update: 31 May 2017
At a glance
- Drugs Ranirestat (Primary)
- Indications Diabetic neuropathies
- Focus Registrational; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 25 Jul 2016 Status changed from recruiting to completed.
- 22 Feb 2012 Additional source identified and integrated: Japic Clinical Trials Information
- 22 Feb 2012 New trial record